SCHEMBL4159984

SCHEMBL4159984

Cc1cccc2nc(CCl)n(C)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HCRTR1 O43613 1/20 0.44
TLR8 Q9NR97 1/20 0.43
PKM P14618 1/20 0.40
PRMT5 O14744 1/20 0.40
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
CRHR1 P34998 1/20 0.38
PDE10A Q9Y233 1/20 0.38
CASR P41180 1/20 0.37
PSMB8 P28062 1/20 0.37
HTR3E A5X5Y0 2/20 0.37
HTR3B O95264 2/20 0.37
HTR3A P46098 2/20 0.37
HTR3D Q70Z44 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8235216 0.83 TLR8 (0.47) NPC1RAB9AMEN1KMT2AHCRTR1
SCHEMBL102626 0.83 PRMT5 (0.60) NPC1RAB9AMEN1KMT2APKM
SCHEMBL1161336 0.79 RAB9A (0.47) NPC1RAB9AMEN1KMT2APKM
SCHEMBL10429871 0.79 TLR8 (0.54) NPC1RAB9AMEN1KMT2AHCRTR1
SCHEMBL1161620 0.78 PSMB8 (0.47) NPC1RAB9AMEN1KMT2APRMT5
SCHEMBL10173803 0.78 PIK3CD (0.50) CDK1CCNB1CCNE1CDK2CASR
SCHEMBL16806054 0.76 NPC1 (0.50) NPC1RAB9AMEN1KMT2AHCRTR1
SCHEMBL22502906 0.73 NPC1 (0.47) NPC1RAB9AMEN1KMT2AHCRTR1
SCHEMBL5457312 0.73 PRMT5 (0.66) NPC1RAB9AMEN1KMT2AHCRTR1
SCHEMBL103809 0.73 RAB9A (0.60) NPC1RAB9AMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
EP-2004613-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2008-12-24 EP disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 NPC1 2168/4885RAB9A 3021/4885MEN1 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.